Simultaneous Determination of Osimertinib and its Metabolites in Human Plasma for Clinical Applications Using High-Performance Liquid Chromatography–Tandem Mass Spectrometry
The method met all the validation criteria and was successfully applied to clinical samples from patients with nonsmall cell lung cancer. Furthermore, the correlation between steady-state trough concentrations of osimertinib, AZ5104, and AZ7550 and patients' baseline characteristics were explored. Women exhibited a significantly higher C min, ss for AZ7550 ( P = 0.023). In addition, body mass index was associated with the C min, ss of both AZ5104 ( P = 0.047) and AZ7550 ( P = 0.001).
Authors
- Guojin Zhou
- Liuxian Guo (ORCID: https://orcid.org/0009-0008-3629-9979)
- Jie Chen (ORCID: https://orcid.org/0000-0001-5094-3195)
- Jing Xu (ORCID: https://orcid.org/0000-0003-0070-0907)
- Jingjing Wu (ORCID: https://orcid.org/0000-0002-5046-9996)
- Yawen Wang (ORCID: https://orcid.org/0000-0001-9562-688X)
- Kejing Tang (ORCID: https://orcid.org/0000-0002-5454-4666)
Institutions
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1097/ftd.0000000000001355
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52